Genmab's Arzerra positive in front-line NHL Phase II trial
This article was originally published in Scrip
Executive Summary
Combination therapy with Genmab's lead drug candidate, Arzerra (ofatumumab), has yielded promising results in a Phase II trial for previously untreated follicular non-Hodgkin's lymphoma (NHL), providing the company with some relief after Arzerra's Phase III failure for refractory follicular NHL nearly two weeks ago.